JOP20190181A1 - مركب برولين أميد به استبدال بواسطة فينيل داي فلوروميثيل - Google Patents
مركب برولين أميد به استبدال بواسطة فينيل داي فلوروميثيلInfo
- Publication number
- JOP20190181A1 JOP20190181A1 JOP/2019/0181A JOP20190181A JOP20190181A1 JO P20190181 A1 JOP20190181 A1 JO P20190181A1 JO P20190181 A JOP20190181 A JO P20190181A JO P20190181 A1 JOP20190181 A1 JO P20190181A1
- Authority
- JO
- Jordan
- Prior art keywords
- cathepsin
- compound
- phenyldifluoromethyl
- present
- inhibitory effect
- Prior art date
Links
- -1 prolinamide compound Chemical class 0.000 title abstract 3
- 108090000613 Cathepsin S Proteins 0.000 abstract 3
- 102100035654 Cathepsin S Human genes 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 2
- 206010052779 Transplant rejections Diseases 0.000 abstract 2
- 230000007815 allergy Effects 0.000 abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 2
- 210000001185 bone marrow Anatomy 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 2
- 229940122805 Cathepsin S inhibitor Drugs 0.000 abstract 1
- 208000005777 Lupus Nephritis Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
[المشكلة] توفير مركب مفيد كمثبط كاثيبسين S [وسيلة الحل] لقد فحص المخترعون الحاليون مركباً له تأثير ثبيطي على كاثيبسين S ويعد مفيداً كمكون فعال لتركيبة صيدلانية للوقاية من و/أوعلاج مرض مناعة ذاتية يشمل ذئبة حمراء جهازية (SLE)، والتهاب كلية ذئبي، أنواع حساسية، أو رفض طعم لعضو، نخاع عظم أو نسيج، ووجدوا أن مركب برولين أميد به استبدال بواسطة فينيل داي فلوروميثيل للاختراع الحالي له تأثير تثبيطي على كاثبيسين S، وبالتالي أكملوا الاختراع الحالي. مركب برولين أميد الذي به استبدال بواسطة فينيل داي فلوروميثيل للاختراع الحالي له تأثير تثبيطي على كاثيبسين S ويعد مفيداً كعامل للوقاية من و/أوعلاج مرض مناعة ذاتية يشمل يشمل SLE والتهاب كلية، أنواع حساسية، أو رفض طعم لعضو، نخاع عظم أو نسيج.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017010321 | 2017-01-24 | ||
| PCT/JP2018/001927 WO2018139438A1 (ja) | 2017-01-24 | 2018-01-23 | フェニルジフルオロメチル置換プロリンアミド化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JOP20190181A1 true JOP20190181A1 (ar) | 2019-07-22 |
| JOP20190181B1 JOP20190181B1 (ar) | 2023-09-17 |
Family
ID=62979051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2019/0181A JOP20190181B1 (ar) | 2017-01-24 | 2018-01-23 | مركب برولين أميد به استبدال بواسطة فينيل داي فلوروميثيل |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US10322997B2 (ar) |
| EP (1) | EP3575284B1 (ar) |
| JP (1) | JP7001068B2 (ar) |
| KR (1) | KR102553613B1 (ar) |
| CN (2) | CN111574422B (ar) |
| AR (1) | AR110767A1 (ar) |
| AU (1) | AU2018211735B2 (ar) |
| BR (1) | BR112019014788A2 (ar) |
| CA (1) | CA3050224A1 (ar) |
| CO (1) | CO2019009090A2 (ar) |
| CY (1) | CY1124906T1 (ar) |
| DK (1) | DK3575284T3 (ar) |
| ES (1) | ES2892400T3 (ar) |
| HR (1) | HRP20211613T1 (ar) |
| HU (1) | HUE056920T2 (ar) |
| IL (1) | IL268060B (ar) |
| JO (1) | JOP20190181B1 (ar) |
| LT (1) | LT3575284T (ar) |
| MA (1) | MA47380A (ar) |
| MX (1) | MX379651B (ar) |
| MY (1) | MY195587A (ar) |
| PH (1) | PH12019501645A1 (ar) |
| PL (1) | PL3575284T3 (ar) |
| PT (1) | PT3575284T (ar) |
| RS (1) | RS62477B1 (ar) |
| SG (1) | SG11201906777TA (ar) |
| SI (1) | SI3575284T1 (ar) |
| TW (1) | TWI764976B (ar) |
| UA (1) | UA124036C2 (ar) |
| WO (1) | WO2018139438A1 (ar) |
| ZA (1) | ZA201904741B (ar) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2312861C2 (ru) * | 2002-03-05 | 2007-12-20 | Мерк Фросст Кэнада Лтд. | Ингибиторы катепсин-цистеинпротеазы |
| JP2010121918A (ja) | 2008-11-17 | 2010-06-03 | Hiroyoshi Asada | 鍋等の取っ手部分の焼き焦げ防止具。 |
| MX2011011094A (es) * | 2009-04-20 | 2011-11-04 | Hoffmann La Roche | Derivados de prolina como inhibidores de catepsina. |
| US7893099B2 (en) * | 2009-06-11 | 2011-02-22 | Hoffman-La Roche Inc. | Cyclopentane derivatives |
| JP2012059507A (ja) | 2010-09-08 | 2012-03-22 | Panasonic Corp | 基板間接続コネクタ構造 |
| US8524710B2 (en) | 2010-11-05 | 2013-09-03 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives |
| AU2012334123B2 (en) * | 2011-11-11 | 2016-12-15 | F. Hoffmann-La Roche Ag | Process for the preparation of 1-acyl-4-phenylsulfonylprolinamide derivatives and new intermediates |
| CN104114549A (zh) * | 2012-02-17 | 2014-10-22 | 霍夫曼-拉罗奇有限公司 | 新型吡咯烷衍生物 |
| SG11201500900YA (en) | 2012-08-21 | 2015-03-30 | Hoffmann La Roche | Novel pyridine derivatives |
| RU2692799C2 (ru) * | 2013-10-08 | 2019-06-27 | Мерк Шарп И Доум Корп. | Ингибиторы цистеинпротеаз катепсинов |
| WO2015051479A1 (en) * | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| SI3419970T1 (sl) | 2016-02-26 | 2020-04-30 | F. Hoffmann-La Roche Ag | Novi pirolidinski derivati |
-
2018
- 2018-01-23 TW TW107102307A patent/TWI764976B/zh not_active IP Right Cessation
- 2018-01-23 CN CN202010529596.XA patent/CN111574422B/zh not_active Expired - Fee Related
- 2018-01-23 UA UAA201908429A patent/UA124036C2/uk unknown
- 2018-01-23 BR BR112019014788-8A patent/BR112019014788A2/pt not_active Application Discontinuation
- 2018-01-23 RS RS20211299A patent/RS62477B1/sr unknown
- 2018-01-23 PL PL18744079T patent/PL3575284T3/pl unknown
- 2018-01-23 MA MA047380A patent/MA47380A/fr unknown
- 2018-01-23 CA CA3050224A patent/CA3050224A1/en active Pending
- 2018-01-23 AU AU2018211735A patent/AU2018211735B2/en not_active Ceased
- 2018-01-23 JP JP2018564576A patent/JP7001068B2/ja not_active Expired - Fee Related
- 2018-01-23 LT LTEPPCT/JP2018/001927T patent/LT3575284T/lt unknown
- 2018-01-23 HU HUE18744079A patent/HUE056920T2/hu unknown
- 2018-01-23 JO JOP/2019/0181A patent/JOP20190181B1/ar active
- 2018-01-23 MX MX2019008756A patent/MX379651B/es unknown
- 2018-01-23 AR ARP180100143A patent/AR110767A1/es not_active Application Discontinuation
- 2018-01-23 MY MYPI2019004186A patent/MY195587A/en unknown
- 2018-01-23 CN CN201880008062.3A patent/CN110248925B/zh not_active Expired - Fee Related
- 2018-01-23 HR HRP20211613TT patent/HRP20211613T1/hr unknown
- 2018-01-23 ES ES18744079T patent/ES2892400T3/es active Active
- 2018-01-23 SI SI201830429T patent/SI3575284T1/sl unknown
- 2018-01-23 PT PT18744079T patent/PT3575284T/pt unknown
- 2018-01-23 KR KR1020197021643A patent/KR102553613B1/ko active Active
- 2018-01-23 EP EP18744079.7A patent/EP3575284B1/en active Active
- 2018-01-23 SG SG11201906777TA patent/SG11201906777TA/en unknown
- 2018-01-23 DK DK18744079.7T patent/DK3575284T3/da active
- 2018-01-23 WO PCT/JP2018/001927 patent/WO2018139438A1/ja not_active Ceased
- 2018-11-05 US US16/180,862 patent/US10322997B2/en active Active
-
2019
- 2019-04-25 US US16/394,571 patent/US10532979B2/en active Active
- 2019-07-15 IL IL268060A patent/IL268060B/en unknown
- 2019-07-15 PH PH12019501645A patent/PH12019501645A1/en unknown
- 2019-07-18 ZA ZA2019/04741A patent/ZA201904741B/en unknown
- 2019-08-22 CO CONC2019/0009090A patent/CO2019009090A2/es unknown
-
2021
- 2021-10-26 CY CY20211100928T patent/CY1124906T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020010369A (es) | Particulas implantables y metodos relacionados. | |
| NZ775660A (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| EP4578450A3 (en) | Solid forms of a cdk4 inhibitor | |
| MX2023002507A (es) | Inhibidores de cd73. | |
| GEAP202114943A (en) | Aromatic sulfonamide derivatives | |
| WO2005032465A3 (en) | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists | |
| WO2003073986A3 (en) | Aminoalkylphosphonates and related compounds as edg receptor agonists | |
| WO2003074008A3 (en) | Aminoalkylphosphonates and related compounds as edg receptor agonists | |
| PH12019502277A1 (en) | Crystalline forms of (s)-afoxolaner | |
| GEP20217318B (en) | Pyrazole magl inhibitors | |
| WO2017123568A3 (en) | Methods for the treatment of myeloid derived suppressor cells related disorders | |
| PH12021552741A1 (en) | Solid forms of a glyt1 inhibitor | |
| PH12017500436A1 (en) | Novel pharmaceutical composition for prevention and/or treatment of urinary incontinence | |
| EA201491876A1 (ru) | Азотсодержащее бициклическое ароматическое гетероциклическое соединение | |
| SG11201804160SA (en) | Composition for inhibiting carnosine dipeptidase | |
| FR3089117B1 (fr) | Compositions cosmétiques déodorantes anhydres comprenant du carbonate de calcium | |
| MY195587A (en) | Phenyldifluoromethyl-Substituted Prolineamide Compound | |
| PH12019502580B1 (en) | Synergistic compositions comprising (r)-dimiracetam (1) and (s)-dimiracetam (2) in a non-racemic ratio | |
| EA201992413A1 (ru) | Противогрибковые средства, используемые в комбинации | |
| KR102239074B9 (ko) | IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 비만의 예방 또는 치료용 약학 조성물 | |
| PH12019502696A1 (en) | Resorbable biodegradable medical and cosmetic composition comprising poly(1,3-trimethylene carbonate) | |
| EA202090432A1 (ru) | Новые соединения, активирующие путь nrf2 | |
| EP3925623A4 (en) | MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BONE DISEASES | |
| EA202190615A1 (ru) | Кристаллическая форма треосульфана | |
| TH1901004515A (th) | ไพรลินาไมด์ที่ถูกแทนที่ฟีนิลไดฟลูออโรเมทธิล |